Different SNPs in Fasciola hepatica P-glycoprotein from diverse Latin American populations are not associated with Triclabendazole resistance.

@article{Solana2018DifferentSI,
  title={Different SNPs in Fasciola hepatica P-glycoprotein from diverse Latin American populations are not associated with Triclabendazole resistance.},
  author={M. V. Solana and M. F. Dom{\'i}nguez and S. Scarcella and Santiago Rad{\'i}o and P. Smircich and S. Fern{\'a}ndez and H. Solana and J. Tort},
  journal={Molecular and biochemical parasitology},
  year={2018},
  volume={224},
  pages={
          57-60
        }
}
  • M. V. Solana, M. F. Domínguez, +5 authors J. Tort
  • Published 2018
  • Biology, Medicine
  • Molecular and biochemical parasitology
  • The use of Triclabendazole for controlling fasciolosis is compromised by increased drug resistance affecting livestock and humans. Although the mode of action of TCBZ is still unknown, putative candidates and markers of resistance have been advanced. A single nucleotide polymorphism (T687 G) in F. hepatica PGP was proposed as marker of resistance in a small scale study of European susceptible and resistant flukes, but the association was not found in Australian samples. The T687 G SNP was… CONTINUE READING
    2 Citations
    Drug resistance in liver flukes
    • 12
    • Highly Influenced

    References

    SHOWING 1-10 OF 26 REFERENCES
    The T687G SNP in a P-glycoprotein gene of Fasciola hepatica is not associated with resistance to triclabendazole in two resistant Australian populations.
    • 15
    • Highly Influential
    Pleiotropic alterations in gene expression in Latin American Fasciola hepatica isolates with different susceptibility to drugs
    • 10
    Molecular characterization and phylogenetic analysis of Fasciola hepatica from Peru.
    • 13
    Resistance of Fasciola hepatica against Triclabendazole in cattle in Cajamarca (Peru): a clinical trial and an in vivo efficacy test in sheep.
    • 66
    Current Threat of Triclabendazole Resistance in Fasciola hepatica.
    • 127
    • PDF
    Understanding triclabendazole resistance.
    • 205
    • PDF